Tortugas Neuroscience
Updated: May 03, 2026
CEO - Jeff Jonas
Country: USA | Funding: $106M (+)
Founded: 2023
Website: https://www.tortugasneuro.com
Tortugas Neuroscience is developing a pipeline of TRTL-107, a D2/D3 partial agonist and 5-HT2A antagonist licensed from China’s Hansoh, and is being evaluated for schizophrenia. The other drug licensed from Hansoh is a GABA receptor-positive allosteric modulator aimed at treating tinnitus.
Founded: 2023
Website: https://www.tortugasneuro.com
Tortugas Neuroscience is developing a pipeline of TRTL-107, a D2/D3 partial agonist and 5-HT2A antagonist licensed from China’s Hansoh, and is being evaluated for schizophrenia. The other drug licensed from Hansoh is a GABA receptor-positive allosteric modulator aimed at treating tinnitus.
